| 1.32 0.1 (8.2%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.7 | 1-year : | 1.91 |
| Resists | First : | 1.46 | Second : | 1.63 |
| Pivot price | 1.29  |
|||
| Supports | First : | 1.16 | Second : | 0.97 |
| MAs | MA(5) : | 1.24 |
MA(20) : | 1.33 |
| MA(100) : | 1.57 |
MA(250) : | 1.98 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24 |
D(3) : | 18.4 |
| RSI | RSI(14): 44.9 |
|||
| 52-week | High : | 4.21 | Low : | 0.93 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IPA ] has closed below upper band by 41.1%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.33 - 1.34 | 1.34 - 1.35 |
| Low: | 1.19 - 1.2 | 1.2 - 1.21 |
| Close: | 1.31 - 1.32 | 1.32 - 1.33 |
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Thu, 28 Mar 2024
InterSystems and IPA's Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with ... - Business Wire
Wed, 20 Mar 2024
IPA Enhances Drug Discovery with Carterra LSA - TipRanks.com - TipRanks
Wed, 20 Mar 2024
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments - Business Wire
Wed, 20 Mar 2024
IPA Boosts AI Drug Discovery with Strategic Acquisition - TipRanks.com - TipRanks
Wed, 20 Mar 2024
Is Immunoprecise Antibodies Ltd (IPA) a Good Buy in the Biotechnology Industry? - InvestorsObserver
Thu, 14 Mar 2024
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 13.5 (%) |
| Held by Institutions | 6.7 (%) |
| Shares Short | 318 (K) |
| Shares Short P.Month | 32 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.88 |
| Profit Margin | -60.3 % |
| Operating Margin | -53.7 % |
| Return on Assets (ttm) | -11 % |
| Return on Equity (ttm) | -25.8 % |
| Qtrly Rev. Growth | 20.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.89 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -2.81 |
| PEG Ratio | 0 |
| Price to Book value | 0.69 |
| Price to Sales | 1.46 |
| Price to Cash Flow | -9.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|